MarketVue® Report
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (U.S.), 2022

Syndicated market assessment report driven by primary market research

REPORT STORE

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (U.S.), July 2022

DOWNLOAD SAMPLE REPORT
DOWNLOAD REPORT BROCHURE
The MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
 
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
 
Topics covered in this report:
  • Disease overview: Review the disease pathophysiology and potential druggable targets
  • Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
  • Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
  • Unmet needs: Identify opportunities to address treatment or disease management gaps
  • Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
  • Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
 
Methodology:
Research for the MarketVue®: CIDP report is supported by 8 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research.
 
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
 
Key companies mentioned:
  • Sanofi
  • Argenx
  • Janssen Pharmaceuticals
  • UCB
  • Takeda Pharmaceuticals
 
Key drugs mentioned:
  • IVIg (HyQvia)
  • Rituximab
  • SAR445088
  • Efgartigimod (Vyvgart)
  • Nipocalimab
  • Rozanolixizumab (Rystiggo)
1. DISEASE OVERVIEW
A rare, autoimmune neurological disorder characterized by loss of sensation and motor weakness
Figure 1.1. Clinical presentation of CIDP
CIDP is characterized by motor and/or sensory deficits
Table 1.1. CIDP – Typical and atypical variants
Figure 1.2. Neurologist-reported segmentation of their CIDP patient population
Figure 1.3. Neurologist-reported percentage of patients previously misdiagnosed, incorrectly diagnosed, or not diagnosed in a timely manner
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1 – Diagnosed prevalent cases of CIDP by region
Table 2.1 – Diagnosed prevalent and drug-treated patients in the U.S. and EU5
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1. Diagnostic criteria for CIDP based on EFNS/PNS guidelines
Physician insights on diagnosis of CIDP
Majority of CIDP patients require drug treatment
Treatment overview
Figure 3.2. Treatment goals for CIDP
Figure 3.3. Neurologist-reported percentage of patients receiving some form of drug therapy
Treatment flow for CIDP
Figure 3.4. Treatment algorithm for CIDP
Immunoglobulin therapy is the standard of care
Figure 3.5. Current Treatment Patient Share
Figure 3.6. Neurologist (n=26) rating of current effective therapy effectiveness in CIDP
Upsides and downsides of current CIDP treatments
Neurologists’ perspectives on current treatments
IVIg is an effective and safe front-line treatment
Figure 3.7. IVIg’s advantages observed in clinical practice
IVIg therapy is not without challenges
Figure 3.8. Approximately 30% of IVIg-treated patients have a poor/inadequate response/are refractory to IVIg therapy
Key treatment dynamics that shape disease management and drug use in CIDP
Figure 3.9. Must-know CIDP treatment dynamics for now and the future
Immunomodulating therapies are the future of CIDP therapy
Figure 3.10. Important dynamics of CIDP market evolution
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in CIDP
Figure 4.2. Physician-reported unmet needs in CIDP
Barriers to care – Physician perspectives
Figure 4.3. Percent of patients who see these factors as barriers to receiving drug therapy
Physician perspectives on unmet needs in CIDP
Figure 4.4. U.S. neurologists’ ranking of the need for new treatments in CIDP
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Number of emerging therapies with clinical trial endpoints that align with unmet needs in CIDP
Table 5.1. Comparison of emerging therapy MoAs
The pipeline for CIDP is active with multiple treatments in late-stage trials
Table 5.2. Comparison of ongoing trials of therapies for CIDP
Although emerging therapies with novel mechanisms are exciting, they may not replace IVIg
Figure 5.2. Percentage of neurologists who rated the following emerging target or approach as “promising”1
6. VALUE & ACCESS
Overview
Table 6.1 – Current therapy pricing
Table 6.2. Typical commercial payer coverage of IV Immune Globulin and Subcutaneous Immune Globulin (e.g., United Healthcare, Aetna, BlueCross BlueShield, Cigna)
Key market access dynamics that will continue to shape treatment use
Figure 6.2. Physician-reported key barriers to drug therapy for CIDP patients
Figure 6.2. Physician-reported key barriers to drug therapy for CIDP patients
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
What is the difference between purchasing a published report and requesting a new report?

Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.

How does REACH produce new primary market research reports in 15 business days?

By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.

Who writes REACH reports?

Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.

Does REACH cover both rare and non-rare diseases?

REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.

Can I meet with the team to discuss the report?

Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.

Published Report

Download immediately.


New Report

Updated upon purchase. Delivered in 15 days.


Undecided about purchasing this report?

» Inquire before buying

Reach out to learn more about report bundle discounts

Reach out to our team to learn more about our capabilities and view sample reports.

Contact us